Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008849 | 0.89 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL596661 | 0.83 | SMN1; SMN2 (0.42) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL597657 | 0.83 | SMN1; SMN2 (0.42) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL597741 | 0.83 | ADRA2C (0.41) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL599223 | 0.83 | ADRA2C (0.41) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL3305237 | 0.81 | SLC6A4 (0.56) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL30976497 | 0.81 | SLC6A4 (0.56) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL8510441 | 0.81 | ADRA2C (0.45) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL27985062 | 0.81 | SLC6A4 (0.56) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL2892626 | 0.81 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | CAI SHAOPEI (US) | 2012-11-01 | — | — | US | disclosed |
| US-8299081-B2 | Methods for treating drug resistant cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8222413-B2 | Methods for synthesizing heterocyclic compounds | NOVARTIS AG (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110046376-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20090215793-A1 | Methods for treating drug resistant cancer | NOVARTIS AG | 2009-08-27 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| EP-0154519-B1 | PHOTOACTIVATED POLYMERIZATION OF VINYL MONOMER IN THE PRESENCE OF POLYSILANES AND AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-08-03 | — | — | EP | disclosed |
| US-3943153-A | BACTERICIDES | MERCK & CO., INC. (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | SLC6A2 324/4885SLC6A4 240/4885SLC6A3 765/4885 |
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | KCNJ2, KCNQ2, KCNJ11 | SLC6A2 206/4885SLC6A4 638/4885SLC6A3 519/4885 |
| US-20110046376-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. | NISCH, DOHH, DNPH1 | SLC6A2 1702/4885SLC6A4 2563/4885SLC6A3 3409/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | SLC6A2 189/4885SLC6A4 300/4885SLC6A3 313/4885 |
| US-20090215793-A1 | Methods for treating drug resistant cancer | ABCC1, SLC11A2, SLC10A1 | SLC6A2 113/4885SLC6A4 1018/4885SLC6A3 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.